Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years
NCT05776888
·
clinicaltrials.gov ↗
ACTIVE_NOT_RECRUITING
Status
106
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsing Multiple Sclerosis
Interventions
OTHER:
Ofatumumab
Sponsor
Novartis Pharmaceuticals